Skip to main content
. 2020 Dec 21;64(1):26–41. doi: 10.1021/acs.jmedchem.0c00931

Figure 4.

Figure 4

Design of dual GSK-3β/tau aggregation inhibitors. The 5-arylidene-2,4-thiazolidinedione has been designed taking into consideration that a five-member heterocycle is a moiety present in both GSK-3β and tau aggregation inhibitors and that a planar substituent in position 5 may increase both the selectivity toward GSK-3β and the interactions with the tau fibrils.